We've found
6,786
archived clinical trials in
Dermatology
We've found
6,786
archived clinical trials in
Dermatology
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Updated: 1/3/2017
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Status: Enrolling
Updated: 1/3/2017
Click here to add this to my saved trials
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Updated: 1/10/2017
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated: 1/10/2017
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Updated: 1/10/2017
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated: 1/10/2017
Click here to add this to my saved trials
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Updated: 1/10/2017
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated: 1/10/2017
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Updated: 1/10/2017
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated: 1/10/2017
Click here to add this to my saved trials
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Updated: 1/10/2017
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 1/10/2017
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Updated: 1/10/2017
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 1/10/2017
Click here to add this to my saved trials
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Updated: 1/10/2017
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 1/10/2017
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Updated: 1/10/2017
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 1/10/2017
Click here to add this to my saved trials
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Updated: 1/10/2017
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Status: Enrolling
Updated: 1/10/2017
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Updated: 1/10/2017
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Status: Enrolling
Updated: 1/10/2017
Click here to add this to my saved trials
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Updated: 1/23/2017
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated: 1/23/2017
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Updated: 1/23/2017
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated: 1/23/2017
Click here to add this to my saved trials
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
Updated: 1/23/2017
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195
Status: Enrolling
Updated: 1/23/2017
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
Updated: 1/23/2017
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195
Status: Enrolling
Updated: 1/23/2017
Click here to add this to my saved trials
Impact of the M22-IPL Acne Filter on Acne Vulgaris
Updated: 1/25/2017
Impact of the M22-IPL Acne Filter on Acne Vulgaris
Status: Enrolling
Updated: 1/25/2017
Impact of the M22-IPL Acne Filter on Acne Vulgaris
Updated: 1/25/2017
Impact of the M22-IPL Acne Filter on Acne Vulgaris
Status: Enrolling
Updated: 1/25/2017
Click here to add this to my saved trials
S. Aureus Colonization in Atopic Dermatitis
Updated: 1/31/2017
Staphylococcus Aureus Colonization in Atopic Dermatitis
Status: Enrolling
Updated: 1/31/2017
S. Aureus Colonization in Atopic Dermatitis
Updated: 1/31/2017
Staphylococcus Aureus Colonization in Atopic Dermatitis
Status: Enrolling
Updated: 1/31/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
Updated: 2/7/2017
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Click here to add this to my saved trials